Proteomics contributions to epigenetic drug discovery
PROTEOMICS · 2023
DOI: 10.1002/pmic.202200435 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift PROTEOMICS, 2023. Verfasst von Roberta Noberini und 1 weiteren Autor:innen. Beteiligte Einrichtung: Department of Experimental Oncology, IEO, European Institute of Oncology IRCCS, Milan, Italy. Hauptthemen laut MEDLINE: Histones, Proteomics. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 113 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Horizon 2020 Framework Programme, Associazione Italiana per la Ricerca sul Cancro.
Abstract (Originalsprache)
The combined activity of epigenetic features, which include histone post‐translational modifications, DNA methylation, and nucleosome positioning, regulates gene expression independently from changes in the DNA sequence, defining how the shared genetic information of an organism is used to generate different cell phenotypes. Alterations in epigenetic processes have been linked with a multitude of diseases, including cancer, fueling interest in the discovery of drugs targeting the proteins responsible for writing, erasing, or reading histone and DNA modifications. Mass spectrometry (MS)‐based proteomics has emerged as a versatile tool that can assist drug discovery pipelines from target validation, through target deconvolution, to monitoring drug efficacy in vivo. Here, we provide an overview of the contributions of MS‐based proteomics to epigenetic drug discovery, describing the main approaches that can be used to support different drug discovery pipelines and highlighting how they contributed to the development and characterization of epigenetic drugs.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Experimental Oncology, IEO, European Institute of Oncology IRCCS, Milan, Italy.
- Department of Oncology and Hematology-Oncology, University of Milan, Milan, Italy.
ORCID-Profile: Tiziana Bonaldi
Förderung
- Horizon 2020 Framework Programme
- Associazione Italiana per la Ricerca sul Cancro
Zitieren
APA
Noberini, R., & Bonaldi, T. (2023). Proteomics contributions to epigenetic drug discovery. PROTEOMICS. https://doi.org/10.1002/pmic.202200435
Vancouver
Noberini R, Bonaldi T. Proteomics contributions to epigenetic drug discovery. PROTEOMICS. 2023. doi:10.1002/pmic.202200435
BibTeX
@article{Noberini2023,
author = {Noberini, Roberta and Bonaldi, Tiziana},
title = {Proteomics contributions to epigenetic drug discovery},
journal = {PROTEOMICS},
year = {2023},
doi = {10.1002/pmic.202200435}
}
EUVIMED